ALT

Altimmune Inc.

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$206.8M

Burn Rate (Qtr)

$17.8M

Company Profile

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). P

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

HepTCell

HBV Infection Therapy

Phase 2

TBD

NasoShield (Vaccine)

Anthrax Vaccine

Phase 1b

H2 2020

AdCOVID

COVID-19

Phase 1 Readout

Q1 2021

AdCOVID

COVID-19 Vaccine for symptomatic patients

Phase 1/2 Data readout

Q1 2021

Recent Posts

See what the community is saying - click to see full post

ALT- AdCOVID (intranasal COVID-19 Vaccine) Readout Estimated Q1 2021

Small Cap COVID-19 Vaccine Players

ALT - Announce Potent Respiratory Mucosal T Cell Responses In Preclinical Study Of COVID-19 Vaccine Candidate,

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon